ArticlePloS one2026
Genetic regulatory axis between AGR2 and ESR1 promotes breast cancer progression.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anterior gradient protein 2 (AGR2), a member of the protein disulfide isomerase family, plays a critical role in endoplasmic reticulum proteostasis and has been implicated in breast cancer progression. However, the downstream regulatory programs and signaling pathways governed by AGR2 remain incompletely defined. Here, we employed CRISPR-Cas9-mediated knockout of AGR2 in breast cancer cells to systematically investigate the functional and transcriptional consequences of AGR2 loss. AGR2 depletion resulted in significant suppression of cell migration, invasion, and chemoresistance. Unbiased transcriptomic profiling by RNA sequencing revealed extensive differential gene expression, implicating AGR2 in receptor-mediated signaling, oxidative stress responses, and cell adhesion pathways. Protein-protein interaction network analysis identified several highly connected hub genes within the AGR2-regulated transcriptome, including estrogen receptor alpha (ESR1/ERα), cadherin 1 (CDH1), androgen receptor (AR), lymphocyte cell-specific protein-tyrosine kinase (LCK), S100 calcium binding protein P (S100P), parkin RBR E3 ubiquitin ligase (PRKN), and decay-accelerating factor (CD55). Notably, ERα emerged as a prominent node within this network, consistent with prior reports linking ERα and AGR2 biology. Integration with publicly available epigenomic datasets further supports a potential regulatory connection between ERα-associated chromatin landscapes and AGR2 expression. Together, these findings define AGR2-dependent transcriptional networks in breast cancer and identify ESR1-associated signaling as a key pathway perturbed upon AGR2 loss, providing a foundation for future mechanistic studies targeting this regulatory interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.